Search

Zai Lab Ltd ADR

Avatud

SektorTervishoid

18.28 -0.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.16

Max

18.51

Põhinäitajad

By Trading Economics

Sissetulek

-607K

-51M

Müük

-28M

100M

Aktsiakasum

-0.46

Kasumimarginaal

-51.215

Töötajad

1,784

EBITDA

4.1M

-44M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+66.96% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-331M

2.1B

Eelmine avamishind

19.04

Eelmine sulgemishind

18.28

Uudiste sentiment

By Acuity

43%

57%

160 / 340 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4. aug 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4. aug 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4. aug 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4. aug 2026, 23:51 UTC

News

Cooper-Standard Holdings will present at the J.P. Morgan 2026 Auto Conference on August 12, with a focus on business strategies. Shares traded little changed after hours.

4. aug 2026, 23:51 UTC

News

Teradata Corp shares fell in after-market hours following mixed Q2 results and disappointing Q3 guidance, projecting adjusted EPS of $0.55 to $0.59.

4. aug 2026, 23:51 UTC

News

8x8 Inc. shares are lower in after-market hours following mixed first-quarter results, with revenue exceeding expectations but second-quarter EPS guidance falling short.

4. aug 2026, 23:51 UTC

News

Hyster-Yale Materials Handling shares fell in after-market trading following a second-quarter revenue of $812.9 million and a net loss of $31.6 million.

4. aug 2026, 23:51 UTC

Social Media
News

Arista Networks shares higher in after-market hours following strong second-quarter results, with adjusted EPS of $1.02 and optimistic third-quarter guidance.

4. aug 2026, 23:51 UTC

News
Social Media

Hecla Mining Co reported second-quarter EPS of $0.17 and revenue of $333.85 million, exceeding expectations. Shares are higher in after-market trading.

4. aug 2026, 23:51 UTC

Correlated Moves
ETF Constituents
News
Macro News

Vanguard Information Technology ETF is trading higher in after-market hours, supported by strong earnings from tech stocks and positive sentiment from UBS's coupon payments.

4. aug 2026, 23:46 UTC

News

Teladoc Health faces scrutiny amid revenue miss and lowered outlook. Shares traded roughly flat in after-market hours following the developments.

4. aug 2026, 23:42 UTC

News

Apple Inc. seeks a preliminary injunction against OpenAI amid a legal battle, as shares trade higher in after-market hours.

4. aug 2026, 23:41 UTC

News

Shutterstock shares are higher in after-market hours despite a $155.9 million net loss and a $173.7 million goodwill impairment charge reported for Q2.

4. aug 2026, 23:41 UTC

News

Compass Inc. shares rise in after-market hours following strong Q2 revenue of $4.306 billion and optimistic Q3 guidance of $3.85 billion to $4.05 billion.

4. aug 2026, 23:41 UTC

News
Social Media

Lumen Technologies reported second-quarter revenue of $2.805 billion, exceeding estimates. Shares rose after hours as the company reaffirmed its full-year guidance.

4. aug 2026, 23:41 UTC

News

Flywire Corp reported strong Q2 results, with revenue surpassing estimates. Shares are higher in after-market trading following the raised full-year guidance.

4. aug 2026, 23:41 UTC

News

Community Healthcare Trust shares declined in after-market hours following second-quarter results that missed earnings and revenue expectations. EPS was $0.06 versus an estimated $0.12.

4. aug 2026, 23:41 UTC

News

Bruker shares higher in after-market hours following Jefferies' price target increase to $62.00, maintaining a Buy rating amid broader performance challenges.

4. aug 2026, 23:41 UTC

Social Media
News

Alphabet Inc shares are higher in after-market trading following the expansion of its Gemini feature in Google Classroom for K-12 users.

4. aug 2026, 23:41 UTC

News
Social Media

Zeta Global Holdings reported Q2 revenue of $443 million but shares fell in after-market trading amid mixed reactions and concerns over growth guidance.

4. aug 2026, 23:41 UTC

Social Media
News

Palantir Technologies reported strong second-quarter results but shares fell during after-market hours, overshadowed by broader market gains and mixed sentiment.

4. aug 2026, 23:41 UTC

Social Media
News

Rocket Lab USA Inc secures a $397 million contract from the U.S. Space Force, driving shares higher in after-market trading.

4. aug 2026, 23:41 UTC

News

IDEXX Laboratories reported second-quarter revenue of $1.22 billion, a 9.7% increase year-over-year. Shares are trading higher in after-market hours following the results.

4. aug 2026, 23:41 UTC

Social Media
News

Kratos Defense and Security Solutions reported Q2 revenues of $458.8 million, exceeding estimates. Shares are advancing in after-market trading amid raised sales guidance.

4. aug 2026, 23:36 UTC

News

EOG Resources reported strong Q2 earnings of $5.15 per share and revenues of $8.62 billion, contributing to shares trading higher in after-market hours.

4. aug 2026, 23:36 UTC

News

Alphatec Holdings shares fell in after-market trading following a net loss of $26 million, despite meeting adjusted EPS expectations and exceeding revenue forecasts.

4. aug 2026, 23:36 UTC

News

Dell Technologies reported nearly 40% of revenue now from AI initiatives. Shares are lower in after-market trading following the announcement.

4. aug 2026, 23:36 UTC

News

Marathon Petroleum shares higher in after-market trading, reflecting stable performance and a market capitalization of approximately $91.74 billion.

4. aug 2026, 23:36 UTC

News

Western Union has launched the Stablecard for international transfers, but shares are trading lower in after-market hours following routine trading activity.

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

66.96% tõus

12 kuu keskmine prognoos

Keskmine 30.87 USD  66.96%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Sentiment

By Acuity

160 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat